Resverlogix amended its agreement with Third Eye Capital as administrative agent to extend the maturity date of the its senior secured term loan from August 4, 2019 to September 16, 2019.
Resverlogix will also repay $3 million of the loan and pay an amendment fee of $100,000. After this and previous principal repayments totaling $18.5 million, the remaining principal balance of the Loan will be approximately $11.5 million.
Resverlogix is developing apabetalone, a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
